Portal de Periódicos da CAPES

Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study

2022; Oxford University Press; Volume: 77; Issue: 8 Linguagem: Inglês

10.1093/jac/dkac177

1460-2091

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz, Sergio Moreno‐Fornés, Jordi Aceitón, Andreu Bruguera, Rosa María Vivanco-Hidalgo, Jordi Casabona, Peré Domingo, Jordi Navarro, Arkaitz Imaz, Elisabet Deig, Gemma Navarro, Josep M. Llibre, José M Miró, Esteve Muntada, Anna Esteve, Francisco Fanjul, Vicenç Falcó, Hernando Knobel, Josep Mallolas, Juan Tiraboschi, Adrián Curran, Joaquín Burgos, Boris Revollo, María Pilar Rivero Gracia, María del Mar Gutiérrez, Javier Murillas, Francisco Homar, José Vicente Fernández-Montero, Eva López González, Joaquim Peraire, Lluís Force, Elena León, Miquel Hortos, Ingrid Vilaró, Amat Orti, David Dalmau, Ángeles Jaén, Elisa de Lazzari, Leire Berrocal, Lucía Rodríguez‐Vázquez, Freya Gargoulas, Toni Vanrell, José Carlos, Josep Vilà, Marina Martínez, Bibiana Morell, Maribel Tamayo, Jorge Palacio, Juan Ambrosioni, Montse Laguno, Marı́a Martı́nez-Rebollar, José Luís Blanco, Felipe García, Berta Torres, Lorena de la Mora, Alexy Inciarte, Ainoa Ugarte, Iván Chivite, Ana González-Cordón, Lorna Leal, Antoni Jou, Eugènia Negredo, María Saumoy, Ana Cristina Simões e Silva, Sofía Scévola, Paula Suanzes, Patricia Alvarez, Isabel Mur, Melchor Riera Jaume, Mercedes García‐Gasalla, Maria Àngels Ribas, Antoni A Campins, María Luz Pintos Peñaranda, Marisa Martín, Helem Haydee, Sònia Calzado, Manel Cervantes, Marta Navarro, Antoni Payeras, Carmen Luna, Aroa Villoslada Gelabert, Patrícia Sorní, Marta Molero, Nadia Abdulghani, Thaïs Comella, Rocio Sola, Montserrat Vargas, Consuleo Viladés, Anna Martí, Elena Yeregui, Anna Rull, Pilar Barrufet, Laia Arbonés, Elena Chamarro, Cristina Escrig, Mireia Cairó, Xavier Martínez-Lacasa, Roser Font, Lizza Macorigh, Juanse Hernández,

COVID-19 Clinical Research Studies

Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH).We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes.After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC.TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.